Cart
sales@molnova.com
ARB-272572
CAS No. 2368182-63-0
ARB-272572( —— )
Catalog No. M35168 CAS No. 2368182-63-0
ARB-272572 is a potent inhibitor of programmed cell death ligand 1 (PD-L1) signaling that induces PD-L1 homodimer interactions and produces immunostimulatory activity in human primary cells.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 242 | Get Quote |
|
| 5MG | 312 | Get Quote |
|
| 10MG | 471 | Get Quote |
|
| 25MG | 762 | Get Quote |
|
| 50MG | 1122 | Get Quote |
|
| 100MG | 1485 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameARB-272572
-
NoteResearch use only, not for human use.
-
Brief DescriptionARB-272572 is a potent inhibitor of programmed cell death ligand 1 (PD-L1) signaling that induces PD-L1 homodimer interactions and produces immunostimulatory activity in human primary cells.
-
DescriptionARB-272572 is a potent small-molecule PD-L1 inhibitor with an IC50 value of 400?pM.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayImmunology/Inflammation
-
TargetPD-1/PD-L1
-
RecptorPD-1/PD-L1
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2368182-63-0
-
Formula Weight568.67
-
Molecular FormulaC32H36N6O4
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 125 mg/mL (219.81 mM; Ultrasonic )
-
SMILESO=C(NC1=CC=CC(C=2C=CC=C(NC(=O)C3=NC=C(C=C3)CNCCO)C2C)=C1C)C4=NC=C(C=C4)CNCCO
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Park JJ, et al. Checkpoint inhibition through small molecule-induced internalization of programmed death-ligand 1. Nat Commun. 2021 Feb 22;12(1):1222. ?
molnova catalog
related products
-
PD-1/PD-L1-IN-10
PD-1/PD-L1-IN-10 is an orally active?PD-1/PD-L1?inhibitor (IC50?of 2.7 nM) with potent anticancer efficacy.
-
BMS-200
A potent PD-1/PD-L1 interaction inhibitor with IC50 of 80 nM in a homogenous time-resolved fluorescence binding assay.
-
Sintilimab
Sintilimab (IBI308) is a humanized IgG4 monoclonal antibody with significant anti-tumor activity that restores endogenous anti-tumor T-cell responses by binding to PD-1 and thereby blocking the interaction of PD-1 with its ligands (PD-L1 and PL-L2).
